Phenominer Database Results (28 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BN/SsN blood CD4 cell count to CD8 cell count ratio control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 CD4-positive T cell quantity both 132 days-139 days 211 2690.0 % 17.83 259.0 automated differential white blood cell count test 0 0 65889 114
BN/SsN calculated serum anti-rat type 2 collagen autoantibody titer type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 blood autoantibody amount both 66 days-126 days 13 2.0 null 0.55 2.0 enzyme linked immunosorbent assay 0.0 immunized 10 days variable titer 69965 850
BN/SsN blood CD4 cell count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 CD4-positive T cell quantity both 132 days-139 days 203 3.14 x 1000 cells/ul 0.06 0.79 automated differential white blood cell count test 0 0 65881 114
BN/SsN calculated serum anti-rat type 2 collagen autoantibody titer Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 blood autoantibody amount female 66 days-126 days 7 1.9 null 0.68 1.8 enzyme linked immunosorbent assay 0.0 0 titer 69928 1241
BN/SsN calculated serum anti-porcine type 2 collagen antibody titer type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 blood immunoglobulin amount both 66 days-126 days 13 3.0 null 0.55 2.0 enzyme linked immunosorbent assay 0.0 immunized 10 days variable titer 69964 850
BN/SsN white blood cell count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 leukocyte quantity both 132 days-139 days 207 9.6 x 1000 cells/ul 0.16 2.34 automated total white blood cell count test 0 0 65870 114
BN/SsN blood glucose level glucose solution (2 g/kg) Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 blood glucose amount both 118 days-125 days 220 116.64 mg/dl 1.5 22.32 intraperitoneal glucose tolerance test 0 glucose injection 120 min 65981 114
BN/SsN platelet count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 platelet quantity both 132 days-139 days 208 1037.0 x 1000 /ul 3.47 50.0 automated blood cell counting method 0 0 65927 114
BN/SsN both adrenal glands weight to body weight ratio control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 adrenal gland mass both 167 days-174 days 210 25.1 mg/100g 0.16 2.3 post excision weight measurement 0 0 65992 114
BN/SsN heart weight to body weight ratio control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 heart mass both 167 days-174 days 45 3.4 g/kg 0.02 0.13 post excision weight measurement 0 0 65998 114
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 7 0.0 % in vivo visual assessment 0.0 0 69924 1241
BN/SsN percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 immunized 10 days variable 69961 850
BN/SsN blood neutrophil count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 neutrophil quantity both 132 days-139 days 216 2.36 x 1000 cells/ul 0.05 0.69 automated differential white blood cell count test 0 0 65874 114
BN/SsN blood CD8 cell count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 CD8-positive T cell quantity both 132 days-139 days 200 0.12 x 10E6 cells/ml 0.0 0.02 automated differential white blood cell count test 0 0 65885 114
BN/SsN blood hemoglobin level control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 blood hemoglobin amount both 132 days-139 days 208 17.2 g/dl 0.01 0.2 automated blood cell counting method 0 0 65915 114
BN/SsN white blood cell count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 leukocyte quantity both 132 days-139 days 208 7.2 x 1000 cells/ul 0.08 1.2 automated total white blood cell count test 0 0 65939 114
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 0 69923 1241
BN/SsN body weight loss type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 body mass both 66 days-126 days 13 0.0 % 0.0 0.0 body weighing method 0.0 immunized 10 days variable (weight loss) 69958 850
BN/SsN calculated serum anti-rat type 2 collagen autoantibody titer Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 blood autoantibody amount male 66 days-126 days 13 1.3 null 0.28 1.0 enzyme linked immunosorbent assay 0.0 0 titer 69927 1241
BN/SsN blood glucose level glucose solution (2 g/kg) Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 blood glucose amount both 118 days-125 days 220 156.42 mg/dl 3.48 51.66 intraperitoneal glucose tolerance test 0 glucose injection 30 min 65975 114
BN/SsN blood CD25 cell count to CD4 cell count ratio control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 regulatory T cell quantity both 132 days-139 days 215 18.6 % 0.12 1.71 automated differential white blood cell count test 0 0 65902 114
BN/SsN hematocrit control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 erythrocyte quantity both 132 days-139 days 208 52.4 % 0.11 1.6 automated blood cell counting method 0 0 65909 114
BN/SsN mean corpuscular volume control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 erythrocyte size trait both 132 days-139 days 208 55.3 fl 0.1 1.4 automated blood cell counting method 0 0 65921 114
BN/SsN red blood cell count control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 erythrocyte quantity both 132 days-139 days 208 9.47 x 10E6 cells/ul 0.01 0.13 automated blood cell counting method 0 0 65933 114
BN/SsN blood glucose level glucose solution (2 g/kg) Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 blood glucose amount both 118 days-125 days 220 108.54 mg/dl 1.02 15.12 intraperitoneal glucose tolerance test 0 glucose injection 0 min 65945 114
BN/SsN systolic blood pressure control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 arterial blood pressure trait both 125 days-132 days 220 137.0 mmHg 1.08 16.0 tail cuff piezoplethysmography 0 6-8 readings per sitting 11670 114
BN/SsN both adrenal glands wet weight control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 adrenal gland mass both 167 days-174 days 210 58.0 mg 0.37 5.3 post excision weight measurement 0 0 65985 114
BN/SsN body weight control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 body mass both 70 days 220 246.1 g 0.55 8.1 body weighing method 0 0 66006 114